VBIO 8-K
Valion Bio, Inc. (VBIO)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): |
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer |
||
|
|
|
|
|
|
||||
|
||||
(Address of Principal Executive Offices) |
|
(Zip Code) |
||
Registrant’s Telephone Number, Including Area Code: |
|
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 2.02 Results of Operations and Financial Condition.
The information provided below in “Item 7.01 - Regulation FD Disclosure” of this Current Report is incorporated by reference into this Item 2.02.
Item 7.01 Regulation FD Disclosure.
On November 14, 2023, Tivic Health Systems, Inc. (the "Company") issued a press release regarding the Company’s financial results for its third quarter ended September 30, 2023. A copy of that press release is furnished as Exhibit 99.1 hereto and incorporated herein by reference.
The information set forth under Item 7.01 of this Current Report on Form 8-K (this "Current Report"), including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of such section. The information in Item 7.01 of this Current Report, including Exhibit 99.1, shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any incorporation by reference language in any such filing, except as expressly set forth by specific reference in such a filing. This Current Report will not be deemed an admission as to the materiality of any information in this Current Report that is required to be disclosed solely by Regulation FD.
Forward-Looking Statements
This Current Report, including Exhibit 99.1 attached hereto, contains certain forward-looking statements that involve substantial risks and uncertainties. When used herein, the terms “anticipates,” “expects,” “estimates,” “believes,” “will” and similar expressions, as they relate to us or our management, are intended to identify such forward-looking statements.
Forward-looking statements in this Current Report, including Exhibit 99.1 attached hereto, or hereafter, including in other publicly available documents filed with the Securities and Exchange Commission, reports to the stockholders of the Company and other publicly available statements issued or released by us involve known and unknown risks, uncertainties and other factors which could cause our actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. Such future results are based upon management’s best estimates based upon current conditions and the most recent results of operations. These risks include, but are not limited to, the risks set forth herein and in such other documents filed with the Securities and Exchange Commission, each of which could adversely affect our business and the accuracy of the forward-looking statements contained herein. Our actual results, performance or achievements may differ materially from those expressed or implied by such forward-looking statements.
Item 9.01 Financial Statements and Exhibits.
|
(d) |
Exhibits. |
Exhibit |
|
Description |
|
|
|
99.1 |
|
|
104 |
|
Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101). |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
TIVIC HEALTH SYSTEMS, INC. |
|
|
|
|
Date: |
November 14, 2023 |
By: |
/s/ Jennifer Ernst |
|
|
|
Name: Jennifer Ernst |
Exhibit 99.1
Tivic Reports Third Quarter 2023 Financial Results
71% Gross Profit Increase; 30% Decrease in Operating Expenses
SAN FRANCISCO – (Business Wire) – November 14, 2023 – Tivic Health® Systems, Inc. (“Tivic”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, announced its financial results for the third quarter 2023 ended September 30, 2023 (“Q3 2023”).
Third Quarter 2023 Financial Highlights
Third Quarter 2023 Developments
Management Commentary
Jennifer Ernst, CEO of Tivic, commented, “Building on work over the last three quarters, the company completed a strategic reset that involved reductions in operating overhead, internal reorganization, and a honing of our focus to critical strategic areas. As a result, we significantly reduced net operating loss and improved gross profits.
“This quarter, we began to see continuous improvements pay off as we build a stronger base for the company to grow from moving forward. With increasing margins, quarter-over-quarter revenue growth, and the launch of our first concerted healthcare professional (HCP) focused marketing initiative, we look forward to the final quarter of 2023."
Third Quarter 2023 Financial Review
Revenue for the third quarter 2023 was $282 thousand, a decrease of $195 thousand (or 40.9 %) compared to $477 thousand in the same period 2022, primarily due to the price increase implemented in the second quarter resulting in an 58% decrease in unit sales, offset by a 54% increase in the per unit average sales price.
Cost of sales for the third quarter 2023 was $174 thousand, a decrease of $240 thousand (or 58%) compared to $414 thousand in the same period 2022. The period over period decrease was primarily due to decreased sales volume.
Gross profit for the third quarter 2023 was $108 thousand, an increase of $45 thousand (or 71%) compared to $63 thousand in the same period 2022. The increase was primarily due to price increases, optimization of the supply-chain and product design, and the sales volume over which fixed and semi-fixed costs were allocated.
Total operating expenses were $1.9 million for the third quarter 2023, compared to $2.6 million in the same period 2022. The decrease of $779 thousand, or 30%, is attributable to lower consulting and professional fee expenses as well as other reduced general administrative expenses.
As of September 30, 2023, the company had $5.2 million of cash and cash equivalents.
The company’s MD&A and consolidated financial statements for the third quarter ended September 30, 2023 will be filed with the Securities and Exchange Commission on November 14, 2023 with the company’s Quarterly Report on Form 10-Q. The company's previous public filings may be found on www.sec.gov and can also be located on Tivic’s website at: https://tivichealth.com/investor/#SEC.
Conference Call and Webcast Information
Management will host a webcast/conference call on Tuesday, November 14, 2023 at 1:30 PM PT / 4:30 PM ET to discuss the company’s third quarter 2023 financial results and provide a business update.
The conference call will be available via telephone by dialing toll-free 888-506-0062 for local callers; or 973-528-0011 for international callers and using entry code 302318.
The conference call will also be available via Webcast link: https://www.webcaster4.com/Webcast/Page/2865/49228
An audio replay of the call will be available from the “Investor” page on the Tivic Health website at https://tivichealth.com/investor/.
About Tivic
Tivic is a commercial health tech company advancing the field of bioelectronic medicine. Tivic’s patented technology platform leverages stimulation on the trigeminal, sympathetic, and vagus nerve structures. Tivic’s non-invasive and targeted approach to the treatment of inflammatory chronic health conditions gives consumers and providers drug-free therapeutic solutions with high safety profiles, low risk, and broad applications. Tivic’s first commercial product, ClearUP, is an FDA approved, award-winning, handheld bioelectronic sinus device. ClearUP is clinically proven, doctor-recommended, and is available through online retailers and commercial distributors. For more information, visit http://tivichealth.com @TivicHealth
Forward-Looking Statements
This press release may contain “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Tivic Health Systems, Inc.’s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: market, economic and other conditions; the continued listing of the company’s common stock on the Nasdaq Capital Market; supply chain constraints; macroeconomic factors, including inflation; the company's financial condition; the company’s ability to raise additional capital on favorable terms if and when necessary; changes in regulatory requirements; and unexpected costs, charges or expenses that reduce Tivic’s capital resources. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements. For a discussion of other risks and uncertainties, and other important factors, any of which could cause Tivic’s actual results to differ from those contained in the forward-looking statements, see Tivic’s filings with the SEC, including, its Annual Report on Form 10-K for the year ended December 31, 2022, filed with the SEC on March 31, 2023, under the heading “Risk Factors,” as well as the company’s subsequent filings with the SEC. Forward-looking statements contained in this press release are made as of this date, and Tivic Health Systems, Inc. undertakes no duty to update such information except as required by applicable law.
Investor Contact:
Hanover International, Inc.
[email protected]
Tivic Health Systems, Inc.
Condensed Balance Sheets
(in thousands, except share and per share data)
|
|
September 30, 2023 |
|
|
December 31, 2022 |
|
||
|
|
(Unaudited) |
|
|
(Audited) |
|
||
ASSETS |
|
|
|
|
|
|
||
Cash and cash equivalents |
|
$ |
5,169 |
|
|
$ |
3,517 |
|
Other current assets |
|
|
1,286 |
|
|
|
1,770 |
|
TOTAL CURRENT ASSETS |
|
|
6,455 |
|
|
|
5,287 |
|
PROPERTY AND EQUIPMENT, NET |
|
|
124 |
|
|
|
12 |
|
NONCURRENT ASSETS |
|
|
428 |
|
|
|
557 |
|
TOTAL ASSETS |
|
$ |
7,007 |
|
|
$ |
5,856 |
|
|
|
|
|
|
|
|
||
LIABILITIES AND STOCKHOLDERS’ EQUITY |
|
|
|
|
|
|
||
Accounts payable and accrued expenses |
|
$ |
827 |
|
|
$ |
1,696 |
|
Other current liabilities |
|
|
173 |
|
|
|
163 |
|
TOTAL CURRENT LIABILITIES |
|
|
1,000 |
|
|
|
1,859 |
|
TOTAL LONG-TERM LIABILITIES |
|
|
242 |
|
|
|
367 |
|
STOCKHOLDERS' EQUITY |
|
|
|
|
|
|
||
Common stock |
|
|
— |
|
|
|
— |
|
Additional paid in capital |
|
|
41,408 |
|
|
|
33,272 |
|
Accumulated deficit |
|
|
(35,643 |
) |
|
|
(29,642 |
) |
TOTAL STOCKHOLDERS' EQUITY |
|
|
5,765 |
|
|
|
3,630 |
|
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY |
|
$ |
7,007 |
|
|
$ |
5,856 |
|
Tivic Health Systems, Inc.
Condensed Statements of Operations
(Unaudited)
(in thousands, except share and per share data)
|
|
Three Months Ended September 30, |
|
|
Nine Months Ended September 30, |
|
||||||||||
|
|
2023 |
|
|
2022 |
|
|
2023 |
|
|
2022 |
|
||||
REVENUES |
|
$ |
282 |
|
|
$ |
477 |
|
|
$ |
819 |
|
|
$ |
1,432 |
|
COST OF SALES |
|
|
174 |
|
|
|
414 |
|
|
|
537 |
|
|
|
1,176 |
|
GROSS PROFIT |
|
|
108 |
|
|
|
63 |
|
|
|
282 |
|
|
|
256 |
|
OPERATING EXPENSES |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Research and development |
|
|
337 |
|
|
|
399 |
|
|
|
1,295 |
|
|
|
1,295 |
|
Sales and marketing |
|
|
480 |
|
|
|
487 |
|
|
|
1,390 |
|
|
|
2,291 |
|
General and administrative |
|
|
1,051 |
|
|
|
1,761 |
|
|
|
3,598 |
|
|
|
4,512 |
|
TOTAL OPERATING EXPENSES |
|
|
1,868 |
|
|
|
2,647 |
|
|
|
6,283 |
|
|
|
8,098 |
|
NET OPERATING LOSS |
|
|
(1,760 |
) |
|
|
(2,584 |
) |
|
|
(6,001 |
) |
|
|
(7,842 |
) |
NET LOSS |
|
$ |
(1,760 |
) |
|
$ |
(2,584 |
) |
|
$ |
(6,001 |
) |
|
$ |
(7,842 |
) |
NET LOSS PER SHARE - BASIC AND DILUTED |
|
$ |
(1.48 |
) |
|
$ |
(27.00 |
) |
|
$ |
(10.60 |
) |
|
$ |
(81.00 |
) |
WEIGHTED-AVERAGE NUMBER OF SHARES - BASIC AND DILUTED |
|
|
1,189,821 |
|
|
|
96,777 |
|
|
|
566,228 |
|
|
|
96,713 |
|